Bernstein comes out defending Celgene (CELG -11.5%) this morning after it takes a hit from...
Thursday, June 21, 2012, 10:43 AM ETBernstein comes out defending Celgene (CELG -11.5%) this morning after it takes a hit from withdrawing Revlimid's front line and maintenance applications from Europe, saying the stock looks attractive at current levels. The firm expects the E.U. to eventually approve Revlimid and for the stock to recover over the near term. It reiterates its Outperform rating on the shares.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles